Helicobacter pylori
Softcover reprint of the original 1st ed. 2016
Book Details
Format
Paperback / Softback
ISBN-10
4431566791
ISBN-13
9784431566793
Edition
Softcover reprint of the original 1st ed. 2016
Publisher
Springer Verlag, Japan
Imprint
Springer Verlag, Japan
Country of Manufacture
GB
Country of Publication
GB
Publication Date
Apr 22nd, 2018
Print length
267 Pages
Product Classification:
HaematologyPathologyGastrointestinal & colorectal surgery
Ksh 16,200.00
Werezi Extended Catalogue
0 in stock
Delivery Location
Delivery fee: Select location
Secure
Quality
Fast
This book provides a detailed review of the most recent pathogenetic, diagnostic and therapeutic approaches in connection with Helicobacter pylori, along with priority areas in research and trends in clinical practice to address this significant pathogen acknowledged as the causative agent in a wide range of diseases, including gastric adenocarcinoma, MALT lymphoma and immune thrombocytopenic purpura (ITP). Medical authorities worldwide now recommend a “test and treat” strategy for this bacterial infection. Eradication therapy approaches range from general mass eradication therapy to tailor-made therapy for antibiotic-resistant refractory infection. In regions with high prevalence of H. pylori infection, the infection itself would be considered a major parameter to predict the risk of gastric adenocarcinoma development. The main interest has shifted recently to the risk stratification strategy for gastric cancer development and to the wide-ranging application of its serological prevention program. This book will benefit all gastroenterologists, hematologists, dermatologists, primary care doctors, epidemiologists, physicians who related with community hygiene, as well as basic scientists, particularly microbiologists, bacteriologists, pathologists, molecular biologists, biochemists, immunologists and oncologists.
This book provides a detailed review of the most recent pathogenetic, diagnostic and therapeutic approaches in connection with Helicobacter pylori, along with priority areas in research and trends in clinical practice to address this significant pathogen acknowledged as the causative agent in a wide range of diseases, including gastric adenocarcinoma, MALT lymphoma and immune thrombocytopenic purpura (ITP). Medical authorities worldwide now recommend a “test and treat” strategy for this bacterial infection. Eradication therapy approaches range from general mass eradication therapy to tailor-made therapy for antibiotic-resistant refractory infection. In regions with high prevalence of H. pylori infection, the infection itself would be considered a major parameter to predict the risk of gastric adenocarcinoma development. The main interest has shifted recently to the risk stratification strategy for gastric cancer development and to the wide-ranging application of its serological prevention program.
This book will benefit all gastroenterologists, hematologists, dermatologists, primary care doctors, epidemiologists, physicians who related with community hygiene, as well as basic scientists, particularly microbiologists, bacteriologists, pathologists, molecular biologists, biochemists, immunologists and oncologists.
Get Helicobacter pylori by at the best price and quality guaranteed only at Werezi Africa's largest book ecommerce store. The book was published by Springer Verlag, Japan and it has pages.